-
Product Insights
New![]()
Net Present Value Model: Molecular Partners AG’s MP-0317
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Melanoma Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Melanoma Drug Details:MP-0310 is under development for the treatment of solid tumors including colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Huntington Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MP-101 in Huntington DiseaseDrug Details:MP-101 is under development for the treatment of Huntington’s disease, optic neuritis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Optic Neuritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MP-101 in Optic NeuritisDrug Details:MP-101 is under development for the treatment of Huntington’s disease, optic neuritis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Colorectal Cancer Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Prostate Cancer Drug Details:MP-0310 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Bladder Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Bladder Cancer Drug Details:MP-0310 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Endometrial Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Endometrial Cancer Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Anal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Anal Cancer Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Colorectal Cancer Drug Details:MP-0310 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Cervical Cancer Drug Details:MP-0310 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Gastric Cancer Drug Details:MP-0310 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Malignant Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Malignant Mesothelioma Drug Details:MP-0310 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Ovarian Cancer Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0533 in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MP-0533 in Myelodysplastic Syndrome Drug Details: MP-0533 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Prostate Cancer Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Malignant Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Malignant Mesothelioma Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Bladder Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Bladder Cancer Drug Details:MP-0317 is under development for the treatment of colorectal cancer, ovarian...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-0310 in Ovarian Cancer Drug Details:MP-0310 is under development for the treatment of solid tumors including...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.